{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T06:52:40Z","timestamp":1790751160305,"version":"4.1.0"},"reference-count":57,"publisher":"Impact Journals, LLC","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Aging"],"published-print":{"date-parts":[[2024,2,28]]},"DOI":"10.18632\/aging.205550","type":"journal-article","created":{"date-parts":[[2024,2,14]],"date-time":"2024-02-14T16:06:16Z","timestamp":1707926776000},"page":"3647-3673","source":"Crossref","is-referenced-by-count":2,"title":["Comprehensive analysis of disulfidptosis-related genes: a prognosis model construction and tumor microenvironment characterization in clear cell renal cell carcinoma"],"prefix":"10.18632","volume":"16","author":[{"given":"Bocun","family":"Yi","sequence":"first","affiliation":[{"name":"Department of Urology, Tianjin Institute of Urology, The Second Hospital of Tianjin Medical University, Tianjin, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xifeng","family":"Wei","sequence":"additional","affiliation":[{"name":"Department of Urology, People\u2019s Hospital of Ningxia Hui Autonomous Region, Yinchuan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongze","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Urology, Tianjin Institute of Urology, The Second Hospital of Tianjin Medical University, Tianjin, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liwei","family":"Jing","sequence":"additional","affiliation":[{"name":"Department of Urology, Tianjin Institute of Urology, The Second Hospital of Tianjin Medical University, Tianjin, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shengxian","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Urology, Tianjin Institute of Urology, The Second Hospital of Tianjin Medical University, Tianjin, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Man","family":"Zhang","sequence":"additional","affiliation":[{"name":"Tianjin Key Laboratory of Metabolic Diseases, Tianjin Institute of Endocrinology, Chu Hsien-I Memorial Hospital of Tianjin Medical University, Tianjin, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhengxin","family":"Liang","sequence":"additional","affiliation":[{"name":"Department of Urology, Tianjin Institute of Urology, The Second Hospital of Tianjin Medical University, Tianjin, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ranlu","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Urology, Tianjin Institute of Urology, The Second Hospital of Tianjin Medical University, Tianjin, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhihong","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Urology, Tianjin Institute of Urology, The Second Hospital of Tianjin Medical University, Tianjin, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"7892","published-online":{"date-parts":[[2024,2,14]]},"reference":[{"key":"1","doi-asserted-by":"publisher","first-page":"17009","DOI":"10.1038\/nrdp.2017.9","article-title":"Renal cell carcinoma.","volume":"3","author":"Ficarra","year":"2017","journal-title":"Nat Rev Dis Primers"},{"key":"2","doi-asserted-by":"publisher","first-page":"71","DOI":"10.6004\/jnccn.2022.0001","article-title":"Kidney Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology.","volume":"2","author":"George","year":"2022","journal-title":"J Natl Compr Canc Netw"},{"key":"3","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1038\/s41581-020-00359-2","article-title":"Clear cell renal cell carcinoma ontogeny and mechanisms of lethality.","volume":"1","author":"Rathmell","year":"2021","journal-title":"Nat Rev Nephrol"},{"key":"4","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1016\/j.ccell.2021.03.007","article-title":"Single-cell sequencing links multiregional immune landscapes and tissue-resident T cells in ccRCC to tumor topology and therapy efficacy.","volume":"3","author":"Chen","year":"2021","journal-title":"Cancer Cell"},{"key":"5","doi-asserted-by":"publisher","first-page":"507","DOI":"10.3322\/caac.21411","article-title":"Treatment of renal cell carcinoma: Current status and future directions.","volume":"6","author":"Rini","year":"2017","journal-title":"CA Cancer J Clin"},{"key":"6","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1038\/s41556-023-01091-2","article-title":"Actin cytoskeleton vulnerability to disulfide stress mediates disulfidptosis.","volume":"2","author":"Zhuang","year":"2023","journal-title":"Nat Cell Biol"},{"key":"7","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1007\/s13238-020-00789-5","article-title":"Cystine transporter SLC7A11\/xCT in cancer: ferroptosis, nutrient dependency, and cancer therapy.","volume":"1","author":"Gan","year":"2021","journal-title":"Protein Cell"},{"key":"8","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1038\/s41418-022-01051-7","article-title":"SOCS2-enhanced ubiquitination of SLC7A11 promotes ferroptosis and radiosensitization in hepatocellular carcinoma.","volume":"3","author":"Shao","year":"2023","journal-title":"Cell Death Differ"},{"key":"9","doi-asserted-by":"publisher","first-page":"e152067","DOI":"10.1172\/JCI152067","article-title":"RBMS1 regulates lung cancer ferroptosis through translational control of SLC7A11.","volume":"13","author":"Fan","year":"2021","journal-title":"J Clin Invest"},{"key":"10","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1186\/s13046-023-02675-4","article-title":"Disulfidptosis: a new target for metabolic cancer therapy.","volume":"4","author":"Duan","year":"2023","journal-title":"J Exp Clin Cancer Res"},{"key":"11","doi-asserted-by":"publisher","first-page":"1210","DOI":"10.3390\/cells9051210","article-title":"Drug Repurposing and DNA Damage in Cancer Treatment: Facts and Misconceptions.","volume":"9","author":"Kotsinas","year":"2020","journal-title":"Cells"},{"key":"12","doi-asserted-by":"publisher","first-page":"104814","DOI":"10.1016\/j.bioorg.2021.104814","article-title":"Synthesis and biological evaluation of disulfides as anticancer agents with thioredoxin inhibition.","volume":"11","author":"Fang","year":"2021","journal-title":"Bioorg Chem"},{"key":"13","doi-asserted-by":"publisher","first-page":"851","DOI":"10.3390\/genes13050851","article-title":"A Novel Cuproptosis-Related Prognostic Gene Signature and Validation of Differential Expression in Clear Cell Renal Cell Carcinoma.","volume":"1","author":"Xie","year":"2022","journal-title":"Genes (Basel)"},{"key":"14","doi-asserted-by":"publisher","first-page":"620126","DOI":"10.3389\/fonc.2021.620126","article-title":"TheGene Family Serves as a Prognostic Biomarker in Clear Cell Renal Cell Carcinoma.","volume":"1","author":"Yang","year":"2021","journal-title":"Front Oncol"},{"key":"15","doi-asserted-by":"publisher","first-page":"1207068","DOI":"10.3389\/fonc.2023.1207068","article-title":"An integrative multi-omics analysis based on disulfidptosis-related prognostic signature and distinct subtypes of clear cell renal cell carcinoma.","volume":"1","author":"Qin","year":"2023","journal-title":"Front Oncol"},{"key":"16","doi-asserted-by":"publisher","first-page":"13793","DOI":"10.1007\/s00432-023-05201-3","article-title":"Identification of disulfidptosis-related subtypes and development of a prognosis model based on stacking framework in renal clear cell carcinoma.","volume":"14","author":"Ding","year":"2023","journal-title":"J Cancer Res Clin Oncol"},{"key":"17","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1038\/s41423-020-0488-6","article-title":"The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications.","volume":"1","author":"Zhang","year":"2020","journal-title":"Cell Mol Immunol"},{"key":"18","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1186\/s13059-016-1028-7","article-title":"Comprehensive analyses of tumor immunity: implications for cancer immunotherapy.","volume":"1","author":"Liu","year":"2016","journal-title":"Genome Biol"},{"key":"19","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1146\/annurev-pathol-042020-042741","article-title":"Immune Checkpoint Inhibitors for the Treatment of Cancer: Clinical Impact and Mechanisms of Response and Resistance.","volume":"1","author":"Engleman","year":"2021","journal-title":"Annu Rev Pathol"},{"key":"20","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1038\/ni.3682","article-title":"'Final common pathway' of human cancer immunotherapy: targeting random somatic mutations.","volume":"1","author":"Rosenberg","year":"2017","journal-title":"Nat Immunol"},{"key":"21","doi-asserted-by":"publisher","first-page":"819","DOI":"10.32604\/or.2023.029414","article-title":"Elucidating the clinical and immunological value of m6A regulator-mediated methylation modification patterns in adrenocortical carcinoma.","volume":"3","author":"Li","year":"2023","journal-title":"Oncol Res"},{"key":"22","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1038\/s41588-018-0312-8","article-title":"Tumor mutational load predicts survival after immunotherapy across multiple cancer types.","volume":"5","author":"Motzer","year":"2019","journal-title":"Nat Genet"},{"key":"23","doi-asserted-by":"publisher","first-page":"e27450","DOI":"10.1002\/pbc.27450","article-title":"Impact of cyclophosphamide and etoposide on outcome of clear cell sarcoma of the kidney treated on the National Wilms Tumor Study-5 (NWTS-5).","volume":"6","author":"Green","year":"2019","journal-title":"Pediatr Blood Cancer"},{"key":"24","doi-asserted-by":"publisher","first-page":"120043","DOI":"10.1016\/j.ijpharm.2020.120043","article-title":"Recent advances and prospects in gemcitabine drug delivery systems.","volume":"59","author":"Kesharwani","year":"2021","journal-title":"Int J Pharm"},{"key":"25","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1186\/s13046-021-02026-1","article-title":"Kidney cancer biomarkers and targets for therapeutics: survivin (BIRC5), XIAP, MCL-1, HIF1\u03b1, HIF2\u03b1, NRF2, MDM2, MDM4, p53, KRAS and AKT in renal cell carcinoma.","volume":"4","author":"Ling","year":"2021","journal-title":"J Exp Clin Cancer Res"},{"key":"26","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1002\/path.5022","article-title":"Genomic classifications of renal cell carcinoma: a critical step towards the future application of personalized kidney cancer care with pan-omics precision.","volume":"24","author":"Creighton","year":"2018","journal-title":"J Pathol"},{"key":"27","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1056\/NEJMoa1505917","article-title":"Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma.","volume":"37","author":"Shinbrot","year":"2016","journal-title":"N Engl J Med"},{"key":"28","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1158\/2159-8290.CD-18-0957","article-title":"Transcriptomic Profiling of the Tumor Microenvironment Reveals Distinct Subgroups of Clear Cell Renal Cell Cancer: Data from a Randomized Phase III Trial.","volume":"9","author":"Patel","year":"2019","journal-title":"Cancer Discov"},{"key":"29","doi-asserted-by":"publisher","first-page":"3616","DOI":"10.3390\/cancers14153616","article-title":"New Therapeutic Interventions for Kidney Carcinoma: Looking to the Future.","volume":"1","author":"Aguiari","year":"2022","journal-title":"Cancers (Basel)"},{"key":"30","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/s0165-6147(98)01277-2","article-title":"The pharmacology of apoptosis.","volume":"2","author":"Hajimohamadreza","year":"1999","journal-title":"Trends Pharmacol Sci"},{"key":"31","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s13045-019-0720-y","article-title":"Ferroptosis, a new form of cell death: opportunities and challenges in cancer.","volume":"1","author":"Li","year":"2019","journal-title":"J Hematol Oncol"},{"key":"32","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1038\/s41423-022-00866-1","article-title":"Cuproptosis: a new form of programmed cell death.","volume":"1","author":"Zhou","year":"2022","journal-title":"Cell Mol Immunol"},{"key":"33","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1038\/s41575-019-0109-y","article-title":"Molecular subtypes of pancreatic cancer.","volume":"1","author":"Biankin","year":"2019","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"34","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.semcancer.2016.02.001","article-title":"Targeting arachidonic acid pathway by natural products for cancer prevention and therapy.","volume":"40","author":"Duddukuri","year":"2016","journal-title":"Semin Cancer Biol"},{"key":"35","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1038\/s41392-020-00443-w","article-title":"Metabolism pathways of arachidonic acids: mechanisms and potential therapeutic targets.","volume":"6","author":"Wang","year":"2021","journal-title":"Signal Transduct Target Ther"},{"key":"36","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1080\/1744666X.2016.1214575","article-title":"PD-1\/PD-L1 blockade in renal cell cancer.","volume":"1","author":"Sosman","year":"2017","journal-title":"Expert Rev Clin Immunol"},{"key":"37","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.ccell.2016.08.004","article-title":"T Cell Cancer Therapy Requires CD40-CD40L Activation of Tumor Necrosis Factor and Inducible Nitric-Oxide-Synthase-Producing Dendritic Cells.","volume":"3","author":"Runza","year":"2016","journal-title":"Cancer Cell"},{"key":"38","doi-asserted-by":"publisher","first-page":"3912","DOI":"10.1038\/s41467-020-17704-5","article-title":"Immune phenotyping of diverse syngeneic murine brain tumors identifies immunologically distinct types.","volume":"1","author":"Shah","year":"2020","journal-title":"Nat Commun"},{"key":"39","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.2147\/CMAR.S184368","article-title":"Loss ofexpression promotes malignant phenotypes and correlates with poor prognosis in renal carcinoma.","volume":"1","author":"Li","year":"2019","journal-title":"Cancer Manag Res"},{"key":"40","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s12014-017-9150-4","article-title":"Downregulation of ATP1A1 promotes cancer development in renal cell carcinoma.","volume":"1","author":"Liang","year":"2017","journal-title":"Clin Proteomics"},{"key":"41","doi-asserted-by":"publisher","first-page":"649761","DOI":"10.3389\/fonc.2021.649761","article-title":"High SAA1 Expression Predicts Advanced Tumors in Renal Cancer.","volume":"1","author":"Zhang","year":"2021","journal-title":"Front Oncol"},{"key":"42","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1158\/1541-7786.MCR-21-0924","article-title":"TGF-\u03b2-Induced FLRT3 Attenuation Is Essential for Cancer-Associated Fibroblast-Mediated Epithelial-Mesenchymal Transition in Colorectal Cancer.","volume":"2","author":"Zhao","year":"2022","journal-title":"Mol Cancer Res"},{"key":"43","doi-asserted-by":"publisher","first-page":"918","DOI":"10.7150\/jca.27226","article-title":"Downregulation of PDK4 Increases Lipogenesis and Associates with Poor Prognosis in Hepatocellular Carcinoma.","volume":"1","author":"Yao","year":"2019","journal-title":"J Cancer"},{"key":"44","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1038\/s41577-018-0044-0","article-title":"CD4T cell help in cancer immunology and immunotherapy.","volume":"1","author":"Kastenm\u00fcller","year":"2018","journal-title":"Nat Rev Immunol"},{"key":"45","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1038\/s41467-018-03600-6","article-title":"Breast and pancreatic cancer interrupt IRF8-dependent dendritic cell development to overcome immune surveillance.","volume":"9","author":"Faccio","year":"2018","journal-title":"Nat Commun"},{"key":"46","doi-asserted-by":"publisher","first-page":"409","DOI":"10.3389\/fimmu.2013.00409","article-title":"NKT cells as an ideal anti-tumor immunotherapeutic.","volume":"4","author":"Taniguchi","year":"2013","journal-title":"Front Immunol"},{"key":"47","doi-asserted-by":"publisher","first-page":"5174","DOI":"10.3390\/cancers13205174","article-title":"The Current Landscape of NKT Cell Immunotherapy and the Hills Ahead.","volume":"1","author":"Johnston","year":"2021","journal-title":"Cancers (Basel)"},{"key":"48","doi-asserted-by":"publisher","first-page":"1180732","DOI":"10.3389\/fendo.2023.1180732","article-title":"Machine learning-based signature of necrosis-associated lncRNAs for prognostic and immunotherapy response prediction in cutaneous melanoma and tumor immune landscape characterization.","volume":"1","author":"Song","year":"2023","journal-title":"Front Endocrinol (Lausanne)"},{"key":"49","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1158\/2326-6066.CIR-16-0297","article-title":"Myeloid-Derived Suppressor Cells.","volume":"5","author":"Gabrilovich","year":"2017","journal-title":"Cancer Immunol Res"},{"key":"50","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1093\/bioinformatics\/bts034","article-title":"The sva package for removing batch effects and other unwanted variation in high-throughput experiments.","volume":"2","author":"Storey","year":"2012","journal-title":"Bioinformatics"},{"key":"51","doi-asserted-by":"publisher","first-page":"1572","DOI":"10.1093\/bioinformatics\/btq170","article-title":"ConsensusClusterPlus: a class discovery tool with confidence assessments and item tracking.","volume":"2","author":"Hayes","year":"2010","journal-title":"Bioinformatics"},{"key":"52","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/1471-2105-14-7","article-title":"GSVA: gene set variation analysis for microarray and RNA-seq data.","volume":"1","author":"Guinney","year":"2013","journal-title":"BMC Bioinformatics"},{"key":"53","doi-asserted-by":"publisher","first-page":"e79","DOI":"10.1038\/psp.2013.56","article-title":"Application of ggplot2 to Pharmacometric Graphics.","volume":"2","author":"Murphy","year":"2013","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"54","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1186\/s13148-019-0730-1","article-title":"Statistical predictions with glmnet.","volume":"1","author":"Bohlin","year":"2019","journal-title":"Clin Epigenetics"},{"key":"55","doi-asserted-by":"publisher","first-page":"2017","DOI":"10.21105\/joss.02017","article-title":"ggalluvial: Layered Grammar for Alluvial Plots.","volume":"5","author":"Brunson","year":"2020","journal-title":"J Open Source Softw"},{"key":"56","doi-asserted-by":"publisher","first-page":"2612","DOI":"10.1038\/ncomms3612","article-title":"Inferring tumour purity and stromal and immune cell admixture from expression data.","volume":"4","author":"Stemke-Hale","year":"2013","journal-title":"Nat Commun"},{"key":"57","doi-asserted-by":"publisher","first-page":"e107468","DOI":"10.1371\/journal.pone.0107468","article-title":"pRRophetic: an R package for prediction of clinical chemotherapeutic response from tumor gene expression levels.","volume":"9","author":"Huang","year":"2014","journal-title":"PLoS One"}],"container-title":["Aging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.aging-us.com\/lookup\/doi\/10.18632\/aging.205550","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,5]],"date-time":"2024-03-05T16:01:11Z","timestamp":1709654471000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.aging-us.com\/lookup\/doi\/10.18632\/aging.205550"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,14]]},"references-count":57,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,2,28]]}},"alternative-id":["205550","38358909"],"URL":"https:\/\/doi.org\/10.18632\/aging.205550","relation":{},"ISSN":["1945-4589"],"issn-type":[{"value":"1945-4589","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,14]]}}}